GENETIC TESTING for HEREDITARY CANCER SYNDROMES Resource Guide
Patient Risk Assessment Bracanalysis Colaris Melaris Colaris AP The Testing Process Billing and Insurance Outreach Materials Clinical References and Resources

Multisite 3 BRACAnalysis®
NO MUTATION DETECTED

Multisite 3 BRACAnalysis® involves analysis of only three specific mutations in BRCA1 and BRCA2 for individuals of Ashkenazi Jewish ancestry. Among Ashkenazi Jewish individuals who carry a mutation in BRCA1 or BRCA2 , greater than 80% carry one of these three mutations – 187delAG in BRCA1, 5385insC in BRCA1, or 6174delT in BRCA2.

Download the Results Patient Education Tool
BRACAnalysis® Multisite 3 - No Mutation Detected

A no mutation detected result from Multisite 3 BRACAnalysis® means that none of the three analyzed mutations was detected.

  • If one of the three Multisite 3 mutations has been previously identified in the family, this result is definitive and similar to a Single Site BRACAnalysis® no mutation detected result. Click here for information on a Single Site BRACAnalysis® no mutation detected result. Note: If there is a history of cancer on both sides of the family, this result should be interpreted carefully as there could be a second familial mutation that was not detected by Multisite 3 BRACAnalysis®.

  • In families without a known mutation, this result does not rule out hereditary breast and ovarian cancer. A different mutation in BRCA1 or BRCA2 may be present (a mutation other than the three that were analyzed by Multisite 3 BRACAnalysis®). In this case, the patient may Reflex to Comprehensive BRACAnalysis®. Some individuals of Ashkenazi Jewish ancestry carry a less common BRCA1 or BRCA2 mutation that can only be detected through full sequencing of the gene. Further testing may be indicated based on family cancer history or patient/physician discomfort with a less than comprehensive approach. Note: If the individual who was tested with Multisite 3 BRACAnalysis® has never had breast or ovarian cancer and no mutation has been identified previously in the family, it is recommended that testing an affected relative be considered to help clarify the clinical significance of this individual's negative test result.

Download the Patient Education Tool


« Back to the BRACAnalysis® Test Results page

© 2004-06, Myriad Genetic Laboratories, Inc.


Introduction
Informed Consent Case Study
Want to know more?
Background
BRCA1 and BRCA2 Genes
Cancer Risk
Testing Guidelines
Test Results and Medical Management